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Summary
Background: The DNA repair protein O6-alkylguanine-DNA
alkyl transferase (AT) mediates resistance to chloroethylnitro-
soureas. Agents depleting AT such as DTIC and its new ana-
logue temozolomide (TMZ) can reverse resistance to chloro-
ethylnitrosoureas. We report the results of a dose finding study
of TMZ in association with fotemustine.
Patients and methods: Twenty-four patients with metastatic
melanoma or recurrent glioma were treated with escalating
dose of oral or intravenous TMZ ranging from 300 to 700
mg/m2, divided over two days. Fotemustine 100 mg/m2 was
given intravenously on day 2, 4 hours after TMZ. AT depletion
was measured in peripheral blood mononuclear cells (PBMCs)
and in selected cases in melanoma metastases and was com-
pared to TMZ pharmacokinetics.
Results: The maximum tolerated dose (MTD) of TMZ was
400 mg/m2 (200 mg/m2/d) when associated with fotemustine
the 2nd day with myelosuppression as dose limiting toxicity.
The decrease of AT level in PBMCs was progressive and
reached 34% of pretreatment values on day 2. There was how-
ever wide interindividual variability. AT reduction was neither
dose nor route dependent and did not appear to be related to
TMZ systemic exposure (AUC). In the same patients, AT
depletion in tumour did not correlate with the decrease of AT
observed in PBMCs.
Conclusions: PBMCs may not be used as a surrogate of
tumour for AT depletion. Further study should concentrate on
the pharmacokinetic pharmacodynamic relationship in tumour
to provide the basis for individually tailored therapy.
Key words: melanoma, pharmacodynamics, pharmacokinetics,
temozolomide
Introduction
Chloroethylnitrosoureas are widely used to treat solid
tumours including brain tumours and metastatic mela-
nomas [1]- They act through the formation of DNA
interstrand crosslinks starting with a carbonium ion
attack at the Opposition of the guanine and 6 to 12
hours later binding to the opposite cytidine [2, 3]. There
is a good correlation between the number of interstrand
crosslinks and the cytotoxicity induced by nitrosoureas
[4]. The number of crosslinks depends on the ability of
the cell to remove the chloroethyl group from the gua-
nine before the crosslink is established. This removal is
due to the O6-alkylguanine DNA alkyltransferase (AT)
protein [4, 5]. AT transfers the alkyl group from the
DNA to an AT internal cysteine residue in an irreversible
and self-inactivating reaction [6]. Restoration of activity
requires new protein synthesis [7]. AT level in human
tumour cells correlates inversely with cytotoxicity of
the chloroethylnitrosoureas [8-11]. In vitro resistance to
nitrosourea can be overcome by the use of methylating
agents [12] or O6-benzylguanine [13] to deplete AT levels
in tumour cells. In the rat, dacarbazine (DTIC) has been
shown to be able to deplete AT [14].
In the clinic, a sequential administration of DTIC
and nitrosourea produced a 20% response rate in meta-
static melanoma [15]. Lee et al. have shown that AT
depletion of peripheral blood mononuclear cells was
dependent on the dose of DTIC. However, the inactiva-
tion of AT reached a plateau at the highest dose level of
DTIC, suggesting a saturation of its hepatic metabolism
into 5-(3 methyl-l-triazeno)imidazole-4-carboxamide
(MTIC), its active metabolite [16].
Temozolomide (TMZ) is a recently synthetised imi-
dazotetrazinone derivative. Its activation is independent
of the hepatic microsomal system. At physiological pH,
TMZ undergoes spontaneous degradation to generate
the methylating compound MTIC [17]. TMZ is able to
reverse the resistance to nitrosourea of a L1210 cell
subline in vitro [18]. In phase I studies, leucopenia and
thrombocytopenia were the dose limiting toxicities at
1000 mg/m2 [19]. Antitumour activity was observed in
the treatment of malignant glioma and metastatic mela-
noma [19-21].
Interaction between TMZ and nitrosoureas has never
been studied in the clinic. We initiated a study of a
sequential administration of TMZ and fotemustine
(diethyl-l-3-(2-chloroethyl)-3-nitrosoureido ethyl phos-
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Table 1. Patient characteristics.
Characteristics
Total
Sex
Male
Female
Mean performance status
Mean age (in years)
Primary
Malignant melanoma
High-grade glioma
Previous treatment
None
Chemotherapy
Without DTIC
With DTIC
Immunotherapy
Radiotherapy
n (range)
24
14
10
1 (0-2)
51(31-71)
22
2
12
2
4
4
2
Route and dose of temozolomide (mg/m2, divided over
two days)
300 i.v. 4
500 i.v. 4
700 i.v. 1
300 p.o. 3
500 p.o. 6
400 i.v./p.o. 4
400 p.o./i.v. 2
phonate), a third generation nitrosourea which showed
high activity against metastatic melanoma and brain
metastases from melanoma [22, 23]. The aims of the
study were the following: a) to define the maximal
tolerated dose (MTD) of TMZ administered four hours
before a fixed dose of fotemustine b) to study the AT
depletion in peripheral blood mononuclear cells and in
selected tumour biopsies c) to measure the pharmaco-
kinetics of TMZ in order to relate them to AT depletion.
Vaudois (Lausanne) in 20 mg and 100 mg gelatine capsules, accord-
ing to the recommendations of the CRC. Capsules were ingested
during a light meal. The total dose was also divided over two days.
Ondansetron (8 mg i.v.) was given prophylactically as antiemetic to all
patients.
Dose escalation of TMZ was performed in two groups of patients:
one receiving intravenous infusion, the other oral administration. The
starting dose level of TMZ was 300 mg/m2 (150 mg/m2 x 2 days).
Depending on the encountered toxicity, dose escalation was planned to
500 mg/m2 (250 mg/m2/d) and then to 700 mg/m2 (350 mg/m2/d).
Toxicity was defined as dose limiting if any grade III or IV toxicity
according to WHO criteria was observed [24]. Three consecutive
patients were treated at each dose level. If one patient experienced a
dose limiting toxicity (DLT), three additional patients were enrolled at
the same dose level. If two patients reached DLT, this dose level was
considered as the maximal tolerated dose (MTD). After two patients
experienced DLT at the 500 mg/m2 dose level, the dose of TMZ was
then decreased to 400 mg/m2. In order to study its bioavailability, it
was administered to four patients intravenously on day 1 and orally on
day 2, and to two patients orally on day 1 and intravenously on day 2.
Fotemustine was supplied by IRIS, Courbevoie, France as 4 ml
vials containing 200 mg freezed dried powder that was dissolved in
ethanol. The solution was diluted in a further 250 ml isotonic glucose
and administered as a one hour intravenous infusion. Flask and tubing
were protected from light. Fotemustine was administered at the dose of
100 mg/m2 intravenously on day 2, four hours after the beginning of
TMZ administration, time interval after which the maximum AT
depletion by DTIC has been reported [25],
Due to the limited amount of TMZ available at the time of the
study, TMZ was replaced by DTIC 500 mg/m2 i.v. for the second and
subsequent cycles. The treatment was repeated at a four-week interval
until disease progression.
Toxicity and response evaluation
Follow-up consisted of a weekly blood cell count. Liver and lung
function tests were done before the second cycle of treatment, then
every two cycles. Toxicity was graded according to WHO [24]. Anti-
tumour response was evaluated before the second cycle of treatment,
then every two cycles according to WHO response criteria.
Pharmacokinetics
Patients and methods
Patients with histologically proven metastatic disseminated melanoma
or recurrent high-grade glioma were eligible for the study. The inclu-
sion criteria were ^18 years, performance status $ 2 according to
Eastern Cooperative Oncology Group (ECOG), normal hematological,
hepatic, renal and pulmonary function tests. Each patient had to give a
written informed consent prior to enrolment in the study. Patients
having received chemotherapy within eight weeks or having a history
of lung irradiation were not included. The study was approved by the
local ethics committee.
Drug formulation and treatment schedule
TMZ was supplied by the Cancer Research Campaign (CRC, London,
UK) in 5 ml vials containing 150 mg TMZ in dimethylsulfoxide
(DMSO). The total dose was diluted in 500 ml normal saline and was
administered as a one-hour constant rate infusion. In order to achieve
a substantial decrease of AT at the time of fotemustine administration,
TMZ treatment was divided over two days. TMZ was planned to be
administered by intravenous infusion, but, during the course of the
study, TMZ became available only as a bulk powder. It was then
formulated at the Pharmacy of the Centre Hospitalier Universitaire
Pharmacokinetics of TMZ were studied in plasma on day 1 and 2. Two
ml blood samples were collected into heparinised tubes prior to TMZ
administration and at 30', 1-hour, 1-hour 30', 2-, 3-, 4-, 6-, 12- and
24-hour post administration on days 1 and 2. Blood samples were
immediately centrifuged at 2000 rpm for 10' at 4 °C. An aliquot of I ml
plasma was acidified with 0.1 ml 1 M HCI and stored at -20 °C for
later analysis.
TMZ assay was performed as previously described [26, 27]. In
brief, matrix components were first eliminated by solid phase extrac-
tion on a 100 mg C\% cartridge, with subsequent desorption of TMZ
with methanol. The resulting eluate was evaporated under nitrogen at
room temperature and reconstituted in 200 ul of 0.5% acetic acid
before HPLC analysis on an ODS-column with MeOH 0.5% AcOH,
10 : 90 as solvent system. The lower limit of quantitation was 0.2 ug/ml.
The specifications of the analytical methods were in accordance with
the recommendations promulgated by the Conference Report on bio-
analytical validation [28]. Pharmacokinetic analysis was carried out
using the computer program SIPHAR (4.0, SIMED, Creteil, France).
Pharmacokinetic parameters were calculated by non compartmental
approach. The elimination rate constant was determined as the slope
of monoexponential curve-fit of logarithmic plasma concentrations
versus time. The area under plasma concentration-time curve (AUC)
was obtained by the linear trapezoidal method and the residual area
from the last data point to infinity was estimated as the plasma
concentration at this time divided by the elimination rate constant.
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O*-Alkylguanine DNA alkyltransferase measurement
Heparinized blood samples of 10 ml were collected beforeTMZ and 2,
4, 8 and 24 hours after TMZ administration in prechilled syringes.
Peripheral blood mononuclear cells (PBMCs) were separated from
heparinized blood using Ficoll-Hypaque, washed with phosphate
buffered saline and stored at -80 °C. In selected patients with skin
metastases of malignant melanoma, biopsies were taken one to three
days before and four hours after the beginning of the administration of
TMZ, time interval after which AT inactivation by DTIC reaches its
nadir [25]. Biopsy samples were immediately frozen in liquid nitrogen.
AT assay of PBMCs and of tissue samples was performed as
reported elsewhere [25]. Samples (1-3 x 106 PBMCs or 30-90 mg
tumor tissue) were sonicated, the supernatants were assayed using 10
ug (3H)-methyl DNA that had been reacted with N-(3H)-methyl-N-
nitrosourea 20 Ci/mmol. Activity was expressed as fmol methyl trans-
ferred to protein per mg of protein. AT depletion was expressed as
absolute decline (in fmol/mg) and as percentage of pretreatment value.
The limit of quantitation of the assay was 10 fmol/mg of protein. The
coefficient of variation of the same sample determined in the same day
or in different days of the same week, was within 10% for PBMCs and
15% for tumour samples.
Quantitative immunofluorescence microscopy
Quantitative immunofluorescence microscopy was performed as de-
scribed [29, 30]. Briefly, two paraffin slides from each tumour sample
were stained in parallel, one with a monoclonal antibody against
human alkyltransferase and another without antibody as a negative
control. A positive control of HT29 tumour cells was also included.
The slides were double-labeled with DAPI to delineate the nuclei and
secondary anti-mouse FITC-labeled antibody to visualize AT-specific
staining. The level of fluorescence in nuclei was calculated from the
digitized epifluorescence image, and converted to molecules per
nucleus using bead standards that related fluorescence intensity to
molecules per unit area.
Statistical analysis
The relationship between parameters was evaluated by determination
of the standard linear correlation coefficient (Pearson). The paired
/-test was used to test whether differences between PBMCs and tumour
AT pretreatment values and those at two time intervals were signifi-
cantly different from zero [31, 32].
Results
Patients characteristics
Characteristics of the 24 patients are presented in
Table 1. Six patients with metastatic malignant melano-
ma had received prior chemotherapy and four of them a
regimen containing DTIC. Two patients with glioma
had a recurrent disease after surgery and radiotherapy.
Nine patients received TMZ as an i.v. infusion, nine
patients as p.o. capsules and six patients p.o. and i.v., or
the reverse sequence. Among the 24 patients, one was not
assessable for toxicity due to rapid disease progression.
Dose escalation
Dose escalation in relation to toxicity is presented in
Table 2. Myelosuppression was the dose limiting toxicity
Table 2. Hematological toxicity.
TMZa dose (mg/m )
300 i.v.
(" = 4)
500 i.v.
(n = 4)
700 i.v.
(« = 1)
300 p.o.
(« = 3)
500 p.o.
(« =5)
400i.v./p.o.
(n=6)
Hemoglobin
WBC
Platelet
Hemoglobin
WBC
Platelet
Hemoglobin
WBC
Platelet
Hemoglobin
WBC
Platelet
Hemoglobin
WBC
Platelet
Hemoglobin
WBC
Platelet
WHO toxicity grade
(number of patients)
0
4
4
4
3
1
1
;
3
3
2
3
3
1
3
4
2
1
-
1
2
1
1
1
2
1
1
2
-
1
1
1
1
:
i
3
-
1
1
1
1
-
4
-
-
—
2
1
2
2
2
" TMZ - indicated temozolomide.
of the sequential administration of TMZ and fotemus-
tine. At the 500 mg/m2 dose level (250 mg/m2/d) two
among the five evaluable in the p.o. groiup had leuco-
cytopenia and thrombocytopenia grade 3-4. In the i.v.
infusion group, one among four evaluable patients had
thrombocytopenia grade 3. All the patients who experi-
enced DLT at this dose level were non pretreated. The
patient at 700 mg/m2 i.v. (350 mg/m2/d) also developed
grade 3 thrombocytopenia. Among the six patients who
received 400 mg/m2 (200mg/m2/d) orally and intrave-
nously, two reached a DLT consisting in WHO grade 4
leucopenia, thrombopenia and anemia. One of these
two patients had received nitrosourea as previous che-
motherapy. The dose of 400 mg/m2 (200 mg/m2/d)
should be considered as the MTD of TMZ when asso-
ciated with fotemustine 100 mg/m2 on day 2, four hours
after TMZ. Duration of myelosuppression in patients
who experienced WHO grade 3-4 toxicity was a median
of 35 days (range 26-41 days) and was similar for
leucocytes and platelets. WHO grade 1 and 2 nausea
occured in 28% of the patients despite the antiemetic
prophylaxis by ondansetron. No respiratory symptoms
were observed after one cycle of treatment. Lung func-
tion tests did not show any modification.
We cannot present data on the cumulative toxicity of
this regimen, since only one cycle of TMZ and fotemus-
tine was administered. Among the 19 patients who
received 39 further cycles of DTIC and Fotemustine,
5 experienced WHO grade 3-4 leuco- and thrombocyto-
penia. The toxic events occurred after three cycles in
three patients without toxicity after TMZ and fotemus-
tine but after the first cycle in two patients who had had
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a grade 4 toxicity after TMZ and fotemustine. Three
patients experienced transitory lung toxicity (two WHO
grade 2, one grade 4), after three (one patient) and four
cycles (two patients) of DTIC-Fotemustine (i.e., after a
cumulative dose of DTIC of 1500 and 2000 mg/m2).
Pharmacokinetics
Pertinent pharmacokinetics parameters are reported in
Table 3. A more comprehensive detailed pharmaco-
kinetic evaluation of TMZ is reported elsewhere [28].
Four out of six patients received the MTD (400 mg/m2
divided over two days) i.v. on day 1 and p.o. on day 2
while the last two were on the opposite regimen. Under
controlled conditions (standardized food intake and
posture) the mean bioavailabilty in six patients was 0.96
± 0.1 without any noticeable influence of the adminis-
tration sequence. Pharmacokinetics of TMZ was linear
after i.v. administration with AUC increasing proportion-
nally to the dose in mg/m2 (r - 0.86 and 0.91 for day 1
and day 2, respectively). When considering all patients
having received TMZ by the oral route, the observed
AUC were lower and more variable indicating a marked
inter-patient variability, possibly influenced by the con-
ditions of capsule administration.
As shown in Figure 1, there was some correlation
Table 3. Pharmacokinetic parameters of temozolomide.
TMZ
dose
(mg/m2)
150 i.v.
200 i.v.
250 i.v.
350 i.v.
150 p.o.
200 p.o.
250 p.o.
No.
of
pts
AUC (mg min/1)
mean ± SD
g
mean ± SD
Day 1 Day 2 Day 1 Day 2
1187 ±237
1704 ± 149
2238 ± 396
2819
1206 ±200
1229 ± 14
1383 ±298
1153 ± 122
1376 ± 24
1888 ±289
2367
1108 ±306
1677 ±201
1447 ± 388
7.2 ±2.4 7.1 ±1.8
9.1 ± 1 . 8 7 . 5 ± 0
12.7 ±1.3 10.1 ±2.0
14.5 11.8
5.3 ±2.0
7.1 ± 1.1
7.2 ±2.3
4.2 ± 1.7
8.9 ± 1.5
7.7 ±5.7
a
 AT 200 mg/m2, the four patients on i.v. day 1 were the same as on
p.o. day 2 and the two patients on p.o. day 1 the same as on i.v. day 2.
Time range of Cmax was after i.v. 60-98 minutes on day 1, 50-72
minutes on day 2, after p.o. 40-180 minutes on day 1 and 42-240
minutes on day 2.
(Pearson correlation test) between the degree of leuco-
cytopenia and thrombocytopenia (percent decrease
count at the nadir) and TMZ AUC after i.v. administra-
tion (r = 0.68, P = 0.04 and r = 0.72, P = 0.03, respec-
tively). After oral administration however, TMZ AUC
was not a predictive index of leucocyte and thrombocyte
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Figure I. Relationship between temozolomide area-under-the-curve on day 1 and 2 (TMZ AUC) and the degree of leuco- and thrombocytopenia
(pretreatment count minus count at the nadir/ pretreatment count) in patients who received TMZ intravenously (i.v.), orally (p.o.), intravenously
on day 1 and orally on day 2 (i.v./p.o.) and orally on day 1 and intravenously on day 2 (p.o./i.v.) in association with fotemustine. TMZ was given on
day 1 and 24 hours later on day 2. Fotemustine was given four hours after TMZ on day 2.
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Figure 2. Mean alkyltransferase (AT) decrease in peripheral blood
mononuclear cells (PBMC) of all patients ± standard errors of the
means (SEM).
toxicity. Substantial decrease in thrombocyte and in
leucocyte counts was observed at lower TMZ AUC
when the patients received TMZ by oral route, in com-
parison with those who received TMZ by i.v. infusion.
Pharmacodynamic assessment of AT depletion
AT level in PBMCs was measured in 20 patients on day
1, in 19 patients on day 2 and in 6 patients also after
DTIC, on day 29. Pretreatment values were scattered
ranging from 121 to 1147 fmol/mg protein (mean 376
fmol/mg). In the whole group, mean AT levels after
treatment showed a progressive and cumulative decrease
corresponding to (± SEM) 62% ± 8% of pretreatment
value after eight hours, 52% ± 14% at the time of fote-
mustine administration and reaching its lowest value at
48 hours with 34% ± 7% (Figure 2). AT levels at eight
hours on day 1 and at four hours on day 2 were statisti-
cally different from pretreatment values values (P <
0.0004). The absolute AT decline (pretreatment minus
AT level at the nadir) was directly related to the pretreat-
ment AT level with a correlation coefficient of 0.97. The
most prominent feature was, however, a wide interindi-
vidual variation in the extent of the decline of AT, even
in patients treated at the same dose level. Figure 3, for
example, shows the AT levels in the group of patients
who were given TMZ 250 mg/m2/day by i.v. infusion.
Due to this high interpatient variability, we were unable
to assess differences between doses and routes of admin-
istration. Similarly AT decrease could not be related to
TMZ systemic exposure (TMZ plasma AUC, Figure 4).
Complete AT depletion, was observed at each dose level,
in five patients. AT decrease was observed in patients
who had received previous treatment as well as in non
pretreated patients. However, two out of three patients
who had received DTIC as previous chemotherapy had
no or minimum AT depletion (nadir at 108 and and 77%
0 8 16 24 32 40 48 56 Hours
I tt
T T F
Figure 3. Alkyltransferase (AT) levels (fmol/mg) in peripheral blood
mononuclear cells in four patients who received Temozolomide (T)
250 mg/m2 i.v. T was given on day I and 24 hours later on day 2.
Fotemustine (F) was administered four hours after temozolomide on
day 2.
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Figure 4. Relationship between the temozolomide area-under-the-
curve on day I and 2 and the degree of alkyltransferase (AT) depletion
(percent decrease at the AT nadir) in peripheral blood mononuclear
cells (PBMCs).
of pretreatment level, respectively). Ten patients had
partial or complete recovery of their initial AT level on
day I and five on day 2. PBMCs AT depletion was not
related to myelosuppression (data not shown).
On day 29, AT level reached the pretreatment values
in five among six assessed patients. One patient retained
a low AT level at 22% of its pretreatment value. AT
depletion achieved by 500 mg/m2 DTIC i.v. on day 29
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was more rapid than that observed on day 1 and 2 after
TMZ at 250 mg/m2/d i.v., but the nadir of AT depletion
was similar.
Six patients had biopsies of melanoma skin metas-
tases before and four hours after TMZ administration.
There was also wide interindividual variations in pre-
treatment levels of AT in tumour (mean value 296
fmol/mg, range 133-488 fmol/mg). After TMZ, mean
AT level was 56% ± 15% of pretreatment level in
tumour. It decreased from 19% to 72% in all but one
patient in whom AT level increased by 16%. As shown in
Table 4, there was, in three patients, a discrepancy
between AT inactivation in peripheral blood lympho-
cytes and in tumours. Two patients (patients no. 1 and
no. 6, Table 4) had a decrease in their tumour AT activity
and an increase in their PBMCs AT, one patient (patient
no. 3, Table 4) had an increase in tumour AT and a
decrease in PBMCs AT. The extent of AT depletion in
tumor could not be related to TMZ dose in this small
group of patients. The maximum AT decrease was even
observed in a patient treated at the TMZ lowest dose
level (patient no. 1, Table 4).
Quantitative immunohistochemistry of AT gave results
similar to those obtained with the biochemical method.
For example, a section from a melanoma skin metas-
tasis biopsy taken prior to TMZ treatment showed much
greater AT-specific immunofluorescence than a section
taken 4 hours after treatment (Figure 5). Quantitation
of the nuclear AT-specific staining in this patient showed
a reduction from an average of 44,000 AT molecules per
nucleus before to 16,000 molecules per nucleus after
treatment. The AT appeared to be localized in the cyto-
plasm prior to treatment (panel a), as observed previ-
ously [30], and was depleted from both the nucleus and
cytoplasm after TMZ treatment (panel b).
Clinical assessment and relationship with AT depletion
The antitumour response was not a main goal of this
study. Tumour evaluation on day 28 revealed tumour
progression in five patients and stable disease in 19
patients. Three patients with stable disease had minor
tumour regression: one had the disappearance of multi-
ple skin metastases with the persistance of visceral,
pulmonary and hepatic lesions, another had a radio-
logical improvement of a lung infiltrate and the third
had a 25% radiological decrease of an iliac lymph node.
The 19 patients with stable disease received the treat-
ment as planned with DTIC and fotemustine. Objective
responses were observed in three patients (16%): one
complete response in the patient with the improvement
of a lung infiltrate and 2 partial remissions (in the patient
with the disappearance of skin metastases and in another
one with lung metastases).
AT levels in melanoma were measured in 6 out of 24
patients. This small number did not allow to draw
definite conclusion regarding the relationship between
the AT decrease in the tumour and the clinical response.
Noticeably however, the patient with melanoma skin
metastasis experiencing a complete response had a 70%
Table 4. AT level in peripheral blood mononuclear cells and in tumour
(six patients).
TMZa dose
150 mg/m2/d i.v.
200 mg/m2/d i.v.
200 mg/m2/d i.v.
200 mg/m2/d p.o.
200 mg/m /d p.o.
250 mg/m2/d i.v.
Patient
number
1
2
3
4
5
6
PBMC AT level
(fmol/mg)b
To
104
621
1147
718
631
127
T4h
213
263
298
475
447
156
Tumour AT
level
To
133
256
488
458
212
228
(fmol/mg)
T4h
25
163
570
134
153
80
a
 TMZ - indicates temozolomide.
b
 PBMC AT level for alkyl-transferase level in peripheral blood mono-
nuclear cells.
(a)
* •
Figure 5. Alkyltransferase (AT) immunofluorescence in sections from
biopsies taken before (a) and four hours after (b) Temozolomide. The
AT-specific antibody staining in the sections was visualized with FITC-
secondary antibodies. In the sample taken before (a) note the cyto-
plasmic localization with relatively low nuclear fluorescence (arrow).
decrease of AT level in the tumour biopsy (patient no. 4),
while another patient (no. 3) with rapid tumour progres-
sion had a 17% increase of AT level in the excised tumour.
Discussion
Part of the resistance to nitrosourea is mediated through
the O6-alkylguanine-DNA alkyltransferase protein (AT),
which is depleted by TMZ in vitro and in vivo [33, 34]. To
our knowledge, this is the first report of the clinical
application of the sequential administration of TMZ
and nitrosourea. TMZ administration was divided over
two days to achieve a substantial decrease of AT at the
time of fotemustine administration. The main toxicity
was myelosuppression, including thrombocytopenia and
anemia. The MTD of TMZ was 400 mg/m2 divided over
two days when given in combination with fotemustine
100 mg/m2 the second day, four hours after TMZ.
When the study was initiated, TMZ was available as
injection form only, it then became available as oral
formulation. This form is currently approved for general
use. Thrombocytopenia and leucocytopenia were more
pronounced when TMZ was administered by the oral
route as seen in Figure 1. The toxicity was however not
predictable but occurred generally at lower AUC as
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compared to i.v. administration. Since we confirmed
that the bioavailability of TMZ was close to 1 (i.e. AUC
p.o./AUC i.v. = 1), the difference, observed in this small
group of patients, reflects interpatient variability and
susceptibility to TMZ rather than route dependency.
However, some unrecognized effect of TMZ adminis-
tered by oral route cannot be fully excluded.
For further phase II trials of TMZ in association with
a nitrosourea, a starting dose of 300 mg/m" (150
mg/m2/day) divided over two days should be recom-
mended. This dose should be escalated in patients with-
out toxicity.
However, the cumulative toxicity of this regimen, and
in particuliar the risk of lung toxicity, is not known,
since only one cycle of TMZ and fotemustine was
administered in this study. The pulmonary toxicity that
occurred in three patients after further treatment with
DTIC and fotemustine has been previously reported
after this regimen, and a cumulative dose of DTIC of
1500 mg/m" [15]. Signs of such a toxicity should be
carefully looked for in future phase II trials of TMZ in
association with a nitrosourea.
TMZ clearly showed a linear pharmacokinetics with
AUC increasing proportionally with dose after i.v. ad-
ministration. Pharmacokinetic parameters and bioavail-
ability values found in this study [28] are in good
accordance with those previously published [19].
The progressive and cumulative AT depletion in
PBMCs with wide interindividual variation has been
previously reported after DTIC [16, 25] and after TMZ
[34]. It has been hypothesized that interindividual varia-
bility in AT depletion was due to differences in pharma-
cokinetics of TMZ. However, in our study, the variabil-
ity of TMZ pharmacokinetics did not influence the
absolute, relative or cumulative AT decrease. AT deple-
tion by DTIC was dose dependent [16] but we could not
demonstrate the same dose-response effect after TMZ.
Indeed, there was no clear relationship between the TMZ
dose administered and the extent of AT depletion.
Previous reports have mentioned the heterogeneity of
AT level in liver metastases from colon cancer [32] and
in skin metastases from melanoma [35]. In the same
patient a variation of up to 400% among lesions was
also observed [35]. Although we cannot rule out that the
lower AT levels we observed in melanoma skin metas-
tases after treatment might be due to interlesional heter-
ogeneity, the consistency of the decrease strongly suggests
that it is an effect of the treatment. Interestingly enough,
AT depletion in tumour and in PBMCs were not related.
An analogue observation has been reported in seven
patients with liver metastases from colon cancer treated
with streptozotocin and BCNU [32]. These observations
indicate that depletion of AT in PBMC is a marker for
production of O6-alkylguanine in DNA, but the extent
of depletion in PBMCs may not accurately reflect the
extent of AT depletion in metastases from melanoma
and colon cancer. Inaccessibility prevented AT decrease
assessment in patients with glioma. A direct relationship
between AT depletion in glioma and in PBMCs can
therefore not be excluded.
In our small group of patients maximum AT deple-
tion was observed at all TMZ dose levels in PBMCs and
at the lowest dose level in melanoma. Moreover, AT
depletion in tumour and in PBMCs could not be directly
related to TMZ exposure. If the aim of the TMZ treat-
ment is to sensitize tumour to the action of chloroethyl-
nitrosoureas, it may not be necessary to use the MTD.
Modulation of AT depletion by TMZ might be better
achieved by individualizing the dose of TMZ. Most of
dose adjustment strategies described to date rely on
pharmacokinetic measurements and on dose adjuste-
ment based on pharmacokinetic-pharmacodynamic
models [36]. In clinical practice, it has been successfully
applied to define the doses of methotrexate, carboplatin,
etoposide, teniposide, 5-fluorouracil and suramin [37].
Modulation of AT could be a future approach and
should concentrate on AT measurement in tumour. The
ultimate aim is to provide a model, based on the meas-
urement of AT and its depletion in tumour, to tailor the
administration of AT depleting agents to the individual
patient. Among the agents designed to inactivate AT,
O6-benzylguanine has recently received considerable at-
tention. Unlike TMZ, O6-benzylguanine acts as a direct
inactivator of AT without interaction with DNA and has
no intrinsic tumour activity [38, 39]. In a phase I study in
patients with glioma, it depleted completely AT levels in
glioma without occurrence of toxicity [39]. Phase I trials
defining the optimal dose of the chloroethylnitrosourea
carmustine to be combined with O6-benzylguanine are
ongoing. Preliminary reports seem however to show a
substantial enhancement of the hematologic toxicity of
carmustine by O6-benzylguanine requiring the dose of
carmustine to be decreased [40]. It is however still not
clear which approach offers the best therapeutic window:
either a complete depletion by agents such a O6-benzyl-
guanine but resulting in increased end organ toxicities
necessitating a decrease in the dosage of the alkylating
agent or only a partial depletion by methylating agents
such as TMZ which have intrinsic cytotoxic activities.
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